BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 3:07:00 PM | Browse: 1513 | Download: 1426
 |
Received |
|
2012-12-13 14:47 |
 |
Peer-Review Started |
|
2012-12-13 15:59 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2013-03-19 17:18 |
 |
Revised |
|
|
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2013-07-05 10:33 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2013-07-05 12:11 |
 |
Articles in Press |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2013-08-09 19:00 |
 |
Publish the Manuscript Online |
|
2013-11-17 20:09 |
| Category |
Obstetrics & Gynecology |
| Manuscript Type |
Topic Highlights |
| Article Title |
Pharmacology of cancer chemotherapy drugs for hyperthermic intraperitoneal peroperative chemotherapy in epithelial ovarian cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Kurt Van der Speeten, Anthony O Stuart and Paul H Sugarbaker |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kurt Van der Speeten, MD, PhD, Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600 Genk, Belgium. kurt.vanderspeeten@zol.be |
| Key Words |
Intraperitoneal chemotherapy; Epithelial ovarian cancer; Ifosfamide; Cisplatin; Carboplatin; Taxanes; Pharmacokinetics; Pharmacodynamics |
| Core Tip |
Intraperitoneal (IP) chemotherapy is an important adjuvant treatment strategy in patients with advanced epithelial ovarian cancer. Although the clinical benefits have been demonstrated both in phase Ⅱ and Ⅲ trials, the pharmacologic rationale for this treatment strategy needs to be clarified. This manuscript reviews the pharmacokinetic and pharmacodynamic rationale of IP chemotherapy and analyzes the available data. |
| Publish Date |
2013-11-17 20:09 |
| Citation |
Van der Speeten K, Stuart AO, Sugarbaker PH. Pharmacology of cancer chemotherapy drugs for hyperthermic intraperitoneal peroperative chemotherapy in epithelial ovarian cancer. World J Obstet Gynecol 2013; 2(4): 143-152 |
| URL |
http://www.wjgnet.com/2218-6220/full/v2/i4/143.htm |
| DOI |
http://dx.doi.org/10.5317/wjog.v2.i4.143 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.